which could lead to treatments for the cognitive symptoms of Parkinson's disease ... New Drug Targets for Alzheimer's Identified from Cerebrospinal Fluid Nov. 14, 2024 — Researchers have linked ...

Now, a breakthrough in the lab may help diagnose both diseases before any signs appear. While medicines like Ozempic or ...

Environmental factors like prolonged stress, chronic inflammation and toxic exposure could play a key role in triggering ...

discovered a new factor in the pathology of Parkinson's disease, which in the future may serve as a target for developing new treatments for this terrible ailment, affecting close to 10 million ...

Among these new targets, the stimulation ... Subthalamic nucleus stimulation is an effective treatment for motor complications and dyskinesia in Parkinson's disease, but is less effective on ...

A recently published study by researchers at the University of Arizona Health Sciences found that a tiny protein called PNA5 ...

According to the new study, patients with a slow progression ... A Risky Business: Why Do Some Parkinson's Disease Treatments Affect Decision Making? Sep. 24, 2024 — Parkinson's disease, a ...

Researchers have identified that G-quadruplexes promote harmful protein aggregation in neurodegenerative diseases. Blocking ...

Management of axial signs (postural instability, freezing) and cognitive decline in Parkinson's disease is unsatisfactory with the current medical treatment. Subthalamic nucleus stimulation is an ...

A drug trial underway at Macquarie University is taking advantage of an early warning sign of Parkinson's in the hope of ...

GSK and Vesalius Therapeutics have entered into a strategic partnership worth $650m to discover and develop new treatments for Parkinson’s disease (PD) and one additional neurodegeneration indication.

Parkinson’s disease is a brain disorder that affects about one million people in the U.S. It happens when the brain loses ...